Cargando…
A non-mutated TROP2 fingerprint in cancer genetics
The advent of high throughput DNA sequencing is providing massive amounts of tumor-associated mutation data. Implicit in these analyses is the assumption that, by acquiring a series of hallmark changes, normal cells evolve along a neoplastic path. However, the lack of correlation between cancer risk...
Autores principales: | Guerra, Emanuela, Di Pietro, Roberta, Stati, Gianmarco, Alberti, Saverio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338868/ https://www.ncbi.nlm.nih.gov/pubmed/37456256 http://dx.doi.org/10.3389/fonc.2023.1151090 |
Ejemplares similares
-
The anti-Trop-2 antibody-drug conjugate Sacituzumab Govitecan—effectiveness, pitfalls and promises
por: Guerra, Emanuela, et al.
Publicado: (2022) -
The Dual Role of Necroptosis in Pancreatic Ductal Adenocarcinoma
por: Giansante, Valentina, et al.
Publicado: (2023) -
The 2EF Antibody Targets a Unique N-Terminal Epitope of Trop-2 and Enhances the In Vivo Activity of the Cancer-Selective 2G10 Antibody
por: Guerra, Emanuela, et al.
Publicado: (2023) -
Trop‐2 cleavage by ADAM10 is an activator switch for cancer growth and metastasis
por: Trerotola, Marco, et al.
Publicado: (2021) -
Trop-2 Is a Determinant of Breast Cancer Survival
por: Ambrogi, Federico, et al.
Publicado: (2014)